Targeting roles of inflammatory microenvironment in lung cancer and metastasis

详细信息    查看全文

• 作者：Lin Shi ; Lingyan Wang ; Jiayan Hou ; Bijun Zhu ; Zhihui Min&#8230
• 关键词：Lung cancer ; Inflammation ; Tumor microenvironment ; Cytokines ; Chemokines
• 刊名：Cancer and Metastasis Reviews
• 出版年：2015
• 出版时间：June 2015
• 年：2015
• 卷：34
• 期：2
• 页码：319-331
• 全文大小：1,770 KB
• 参考文献：1.Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008). Cancer-related inflammation. Nature, 454(7203), 436鈥?44.PubMed
  2.Kruse, J. L., & Strouse, T. B. (2015). Sick and tired: mood, fatigue, and inflammation in cancer. Current Psychiatry Reports, 17(3), 555.PubMed
  3.Balkwill, F. R., & Mantovani, A. (2012). Cancer-related inflammation: common themes and therapeutic opportunities. Seminars in Cancer Biology, 22(1), 33鈥?0.PubMed
  4.Bremnes, R. M., Al-Shibli, K., Donnem, T., Sirera, R., Al-Saad, S., Andersen, S., et al. (2011). The role of tumor-infiltrating immune cells and chronic inflammation at the tumor site on cancer development, progression, and prognosis: emphasis on non-small cell lung cancer. Journal of Thoracic Oncology, 6(4), 824鈥?33.PubMed
  5.Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell, 144(5), 646鈥?74.PubMed
  6.Araujo, A., Ribeiro, R., Azevedo, I., Coelho, A., Soares, M., Sousa, B., et al. (2007). Genetic polymorphisms of the epidermal growth factor and related receptor in non-small cell lung cancer鈥攁 review of the literature. The Oncologist, 12(2), 201鈥?10.PubMed
  7.Wu, K., House, L., Liu, W., & Cho, W. C. (2012). Personalized targeted therapy for lung cancer. International Journal of Molecular Sciences, 13(9), 11471鈥?1496.PubMed Central PubMed
  8.Ferlay, J., Parkin, D. M., & Steliarova-Foucher, E. (2010). Estimates of cancer incidence and mortality in Europe in 2008. European Journal of Cancer, 46(4), 765鈥?81.PubMed
  9.Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet-Tieulent, J., & Jemal, A. (2015). Global cancer statistics, 2012. CA: A Cancer Journal for Clinicians, 65(2), 87鈥?08.
  10.Xu, Y., Zhang, J., Han, J., Pan, X., Cao, Y., Guo, H., et al. (2012). Curcumin inhibits tumor proliferation induced by neutrophil elastase through the upregulation of alpha1-antitrypsin in lung cancer. Molecular Oncology, 6(4), 405鈥?17.PubMed
  11.Engels, E. A. (2008). Inflammation in the development of lung cancer: epidemiological evidence. Expert Review of Anticancer Therapy, 8(4), 605鈥?15.PubMed
  12.de-Torres, J. P., Wilson, D. O., Sanchez-Salcedo, P., Weissfeld, J. L., Berto, J., Campo, A., et al. (2015). Lung cancer in patients with chronic obstructive pulmonary disease. Development and validation of the COPD Lung Cancer Screening Score. American Journal of Respiratory and Critical Care Medicine, 191(3), 285鈥?91.PubMed
  13.Dostert, C., Petrilli, V., Van Bruggen, R., Steele, C., Mossman, B. T., & Tschopp, J. (2008). Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science, 320(5876), 674鈥?77.PubMed Central PubMed
  14.Barbieri, S. S., & Weksler, B. B. (2007). Tobacco smoke cooperates with interleukin-1beta to alter beta-catenin trafficking in vascular endothelium resulting in increased permeability and induction of cyclooxygenase-2 expression in vitro and in vivo. The FASEB Journal, 21(8), 1831鈥?843.PubMed
  15.de Visser, K. E., Eichten, A., & Coussens, L. M. (2006). Paradoxical roles of the immune system during cancer development. Nature Reviews Cancer, 6(1), 24鈥?7.PubMed
  16.Zhang, M., He, Y., Sun, X., Li, Q., Wang, W., Zhao, A., et al. (2014). A high M1/M2 ratio of tumor-associated macrophages is associated with extended survival in ovarian cancer patients. Journal of Ovarian Research, 7, 19.PubMed Central PubMed
  17.Schioppa, T., Moore, R., Thompson, R. G., Rosser, E. C., Kulbe, H., Nedospasov, S., et al. (2011). B regulatory cells and the tumor-promoting actions of TNF-alpha during squamous carcinogenesis. Proceedings of the National Academy of Sciences of the United States of America, 108(26), 10662鈥?0667.PubMed Central PubMed
  18.Andreu, P., Johansson, M., Affara, N. I., Pucci, F., Tan, T., Junankar, S., et al. (2010). FcRgamma activation regulates inflammation-associated squamous carcinogenesis. Cancer Cell, 17(2), 121鈥?34.PubMed Central PubMed
  19.DeNardo, D. G., Barreto, J. B., Andreu, P., Vasquez, L., Tawfik, D., Kolhatkar, N., et al. (2009). CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell, 16(2), 91鈥?02.PubMed Central PubMed
  20.Bygd, H. C., Forsmark, K. D., & Bratlie, K. M. (2014). The significance of macrophage phenotype in cancer and biomaterials. Clinical and Translational Medicine, 3, 62.
  21.Barriere, G., Fici, P., Gallerani, G., Fabbri, F., & Rigaud, M. (2015). Epithelial mesenchymal transition: a double-edged sword. Clinical and Translational Medicine, 4, 14.PubMed Central PubMed
  22.Kraman, M., Bambrough, P. J., Arnold, J. N., Roberts, E. W., Magiera, L., Jones, J. O., et al. (2010). Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science, 330(6005), 827鈥?30.PubMed
  23.Luo, H., Tu, G., Liu, Z., & Liu, M. (2015). Cancer-associated fibroblasts: a multifaceted driver of breast cancer progression. Cancer Letters, 361(2), 155鈥?63.PubMed
  24.Wermuth, P. J., & Jimenez, S. A. (2015). The significance of macrophage polarization subtypes for animal models of tissue fibrosis and human fibrotic diseases. Clinical and Translational Medicine, 4, 2.PubMed Central PubMed
  25.Lin, G. N., Peng, J. W., Liu, P. P., Liu, D. Y., Xiao, J. J., & Chen, X. Q. (2014). Elevated neutrophil-to-lymphocyte ratio predicts poor outcome in patients with advanced non-small-cell lung cancer receiving first-line gefitinib or erlotinib treatment. Asia-Pacific Journal of Clinical Oncology. doi:10.鈥?111/鈥媋jco.鈥?2273 .
  26.Gregory, A. D., & Houghton, A. M. (2011). Tumor-associated neutrophils: new targets for cancer therapy. Cancer Research, 71(7), 2411鈥?416.PubMed
  27.Pandey, J. P. (2011). Prognostic immune markers in non-small cell lung cancer鈥攍etter. Clinical Cancer Research, 17(24), 7835鈥?836.PubMed
  28.Ammirante, M., Luo, J. L., Grivennikov, S., Nedospasov, S., & Karin, M. (2010). B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature, 464(7286), 302鈥?05.PubMed Central PubMed
  29.Zhao, P., Bu, X., Wei, X., Sun, W., Xie, X., Li, C., et al. (2015). Dendritic cell immunotherapy combined with cytokine-induced killer cells promotes skewing toward Th2 cytokine profile in patients with metastatic non-small cell lung cancer. International Immunopharmacology, 25(2), 450鈥?56.PubMed
  30.Dyduch, G., Kaczmarczyk, K., & Okon, K. (2012). Mast cells and cancer: enemies or allies? Polish Journal of Pathology, 63(1), 1鈥?.PubMed
  31.Tomassetti, S., Gurioli, C., Ryu, J. H., Decker, P. A., Ravaglia, C., Tantalocco, P., et al. (2015). The impact of lung cancer on survival of idiopathic pulmonary fibrosis. Chest, 147(1), 157鈥?64.PubMed
  32.Lin, W. W., & Karin, M. (2007). A cytokine-mediated link between innate immunity, inflammation, and cancer. Journal of Clinical Investigation, 117(5), 1175鈥?183.PubMed Central PubMed
  33.Aggarwal, B. B. (2003). Signalling pathways of the TNF superfamily: a double-edged sword. Nature Reviews Immunology, 3(9), 745鈥?56.PubMed
  34.Gregorc, V., De Braud, F. G., De Pas, T. M., Scalamogna, R., Citterio, G., Milani, A., et al. (2011). Phase I study of NGR-hTNF, a selective vascular targeting agent, in combination with cisplatin in refractory solid tumors. Clinical Cancer Research, 17(7), 1964鈥?972.PubMed
  35.Kim, V., Rogers, T. J., & Criner, G. J. (2008). New concepts in the pathobiology of chronic obstructive pulmonary disease. Proceedings of the American Thoracic Society, 5(4), 478鈥?85.PubMed Central PubMed
  36.Neuzillet, C., Tijeras-Raballand, A., Cohen, R., Cros, J., Faivre, S., Raymond, E., et al. (2015). Targeting the TGFbeta pathway for cancer therapy. Pharmacology and Therapeutics, 147, 22鈥?1.PubMed
  37.O鈥機onnor, J. W., & Gomez, E. W. (2014). Biomechanics of TGF尾-induced epithelial-mesenchymal transition: implications for fibrosis and cancer. Clinical and Translational Medicine, 3, 23.PubMed Central PubMed
  38.Hasan, M., Neumann, B., Haupeltshofer, S., Stahlke, S., Claudio Fantini, M., Angstwurm, K., et al. (2015). Activation of TGF-beta-induced non-Smad signaling pathways during Th17 differentiation. Immunology and Cell Biology. doi:10.鈥?038/鈥媔cb.鈥?015.鈥?1 .
  39.Heerboth, S., Housman, G., Leary, M., Longacre, M., Byler, S., Lapinska, K., Willbanks, A., & Sarkar, S. (2015). EMT and tumor metastasis. Clinical and Translational Medicine, 4, 6.PubMed Central PubMed
  40.Risolino, M., Mandia, N., Iavarone, F., Dardaei, L., Longobardi, E., Fernandez, S., et al. (2014). Transcription factor PREP1 induces EMT and metastasis by controlling the TGF-beta-SMAD3 pathway in non-small cell lung adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America, 111(36), 3775鈥?784.
  41.Ochoa, C. E., Mirabolfathinejad, S. G., Ruiz, V. A., Evans, S. E., Gagea, M., Evans, C. M., et al. (2011). Interleukin 6, but not T helper 2 cytokines, promotes lung carcinogenesis. Cancer Prevention Research (Philadelphia, Pa.), 4(1), 51鈥?4.
  42.Naugler, W. E., & Karin, M. (2008). The wolf in sheep鈥檚 clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends in Molecular Medicine, 14(3), 109鈥?19.PubMed
  43.Uskudar Teke, H., Gunduz, E., Akay, O. M., Bal, C., & Gulbas, Z. (2015). Are the high serum interleukin-6 and vascular endothelial growth factor levels useful prognostic markers in aggressive non-Hodgkin lymphoma patients? Turkish Journal of Haematology, 32(1), 21鈥?8.PubMed
  44.Song, L., Rawal, B., Nemeth, J. A., & Haura, E. B. (2011). JAK1 activates STAT3 activity in non-small-cell lung cancer cells and IL-6 neutralizing antibodies can suppress JAK1-STAT3 signaling. Molecular Cancer Therapeutics, 10(3), 481鈥?94.PubMed Central PubMed
  45.Yao, Z., Fenoglio, S., Gao, D. C., Camiolo, M., Stiles, B., Lindsted, T., et al. (2010). TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. Proceedings of the National Academy of Sciences of the United States of America, 107(35), 15535鈥?5540.PubMed Central PubMed
  46.Frantzi, M., Bhat, A., & Latosinska, A. (2014). Clinical proteomic biomarkers: relevant issues on study design & technical considerations in biomarker development. Clinical and Translational Medicine, 3, 7.PubMed Central PubMed
  47.Colasante, A., Mascetra, N., Brunetti, M., Lattanzio, G., Diodoro, M., Caltagirone, S., et al. (1997). Transforming growth factor beta 1, interleukin-8 and interleukin-1, in non-small-cell lung tumors. American Journal of Respiratory and Critical Care Medicine, 156(3 Pt 1), 968鈥?73.PubMed
  48.Swindell, W. R., Sarkar, M. K., Stuart, P. E., Voorhees, J. J., Elder, J. T., Johnston, A., & Gudjonsson, J. E. (2015). Psoriasis drug development and GWAS interpretation through in silico analysis of transcription factor binding sites. Clinical and Translational Medicine, 4, 13.PubMed Central PubMed
  49.Erez, N., Truitt, M., Olson, P., Arron, S. T., & Hanahan, D. (2010). Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-dependent manner. Cancer Cell, 17(2), 135鈥?47.PubMed
  50.Camnitz, W., Burdick, M. D., Strieter, R. M., Mehrad, B., & Keeley, E. C. (2012). Dose-dependent effect of statin therapy on circulating CXCL12 levels in patients with hyperlipidemia. Clinical and Translational Medicine, 1, 23.PubMed Central PubMed
  51.Burger, J. A., & Stewart, D. J. (2009). CXCR4 chemokine receptor antagonists: perspectives in SCLC. Expert Opinion on Investigational Drugs, 18(4), 481鈥?90.PubMed
  52.Pfeiffer, M., Hartmann, T. N., Leick, M., Catusse, J., Schmitt-Graeff, A., & Burger, M. (2009). Alternative implication of CXCR4 in JAK2/STAT3 activation in small cell lung cancer. British Journal of Cancer, 100(12), 1949鈥?956.PubMed Central PubMed
  53.Minamiya, Y., Saito, H., Takahashi, N., Ito, M., Imai, K., Ono, T., et al. (2010). Expression of the chemokine receptor CXCR4 correlates with a favorable prognosis in patients with adenocarcinoma of the lung. Lung Cancer, 68(3), 466鈥?71.PubMed
  54.Facciabene, A., Peng, X., Hagemann, I. S., Balint, K., Barchetti, A., Wang, L. P., et al. (2011). Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature, 475(7355), 226鈥?30.PubMed
  55.Danilova, E., Skrindo, I., Gran, E., Hales, B. J., Smith, W. A., Jahnsen, J., Johansen, F. E., Jahnsen, F. L., & Baekkevold, E. S. (2015). A role for CCL28-CCR3 in T-cell homing to the human upper airway mucosa. Mucosal Immunology, 8(1), 107鈥?14.PubMed
  56.Qian, B. Z., Li, J., Zhang, H., Kitamura, T., Zhang, J., Campion, L. R., et al. (2011). CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature, 475(7355), 222鈥?25.PubMed Central PubMed
  57.Targosz, A., Brzozowski, T., Pierzchalski, P., Szczyrk, U., Ptak-Belowska, A., Konturek, S. J., et al. (2012). Helicobacter pylori promotes apoptosis, activates cyclooxygenase (COX)-2 and inhibits heat shock protein HSP70 in gastric cancer epithelial cells. Inflammation Research, 61(9), 955鈥?66.PubMed Central PubMed
  58.Wu, S., Rhee, K. J., Albesiano, E., Rabizadeh, S., Wu, X., Yen, H. R., et al. (2009). A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nature Medicine, 15(9), 1016鈥?022.PubMed Central PubMed
  59.Hessol, N. A., Martinez-Maza, O., Levine, A. M., Morris, A., Margolick, J. B., Cohen, M. H., et al. (2015). Lung cancer incidence and survival among HIV-infected and uninfected women and men. AIDS. PMID: 25888645
  60.Cimato, T. R., & Palka, B. A. (2014). Fractalkine (CX3CL1), GM-CSF and VEGF-a levels are reduced by statins in adult patients. Clinical and Translational Medicine, 3, 14.PubMed Central PubMed
  61.Graves, C. A., Abboodi, F. F., Tomar, S., Wells, J., & Pirisi, L. (2014). The translational significance of epithelial-mesenchymal transition in head and neck cancer. Clinical and Translational Medicine, 3, 39.
  62.Zhang, Y., Wang, L., Zhang, M., Jin, M., Bai, C., & Wang, X. (2012). Potential mechanism of interleukin-8 production from lung cancer cells: an involvement of EGF-EGFR-PI3K-Akt-Erk pathway. Journal of Cellular Physiology, 227(1), 35鈥?3.PubMed
  63.Zong, W. X., & Thompson, C. B. (2006). Necrotic death as a cell fate. Genes and Development, 20(1), 1鈥?5.PubMed
  64.Letzkus, M., Luesink, E., Starck-Schwertz, S., Bigaud, M., Mirza, F., Hartmann, N., et al. (2014). Gene expression profiling of immunomagnetically separated cells directly from stabilized whole blood for multicenter clinical trials. Clinical and Translational Medicine, 3, 36.PubMed Central PubMed
  65.Spitz, M. R., Gorlov, I. P., Amos, C. I., Dong, Q., Chen, W., Etzel, C. J., et al. (2011). Variants in inflammation genes are implicated in risk of lung cancer in never smokers exposed to second-hand smoke. Cancer Discovery, 1(5), 420鈥?29.PubMed Central PubMed
  66.Stueckle, T. A., Lu, Y., Davis, M. E., Wang, L., Jiang, B. H., Holaskova, I., et al. (2012). Chronic occupational exposure to arsenic induces carcinogenic gene signaling networks and neoplastic transformation in human lung epithelial cells. Toxicology and Applied Pharmacology, 261(2), 204鈥?16.PubMed Central PubMed
  67.Landvik, N. E., Tekpli, X., Anmarkrud, K. H., Haugen, A., & Zienolddiny, S. (2012). Molecular characterization of a cancer-related single nucleotide polymorphism in the pro-inflammatory interleukin-1B gene. Molecular Carcinogenesis, 51(Suppl 1), 168鈥?75.
  68.Yan, B., Wang, H., Rabbani, Z. N., Zhao, Y., Li, W., Yuan, Y., et al. (2006). Tumor necrosis factor-alpha is a potent endogenous mutagen that promotes cellular transformation. Cancer Research, 66(24), 11565鈥?1570.PubMed
  69.Karabela, S. P., Kairi, C. A., Magkouta, S., Psallidas, I., Moschos, C., Stathopoulos, I., et al. (2011). Neutralization of tumor necrosis factor bioactivity ameliorates urethane-induced pulmonary oncogenesis in mice. Neoplasia, 13(12), 1143鈥?151.PubMed Central PubMed
  70.Verhelst, K., Verstrepen, L., Carpentier, I., & Beyaert, R. (2013). IkappaB kinase epsilon (IKKepsilon): a therapeutic target in inflammation and cancer. Biochemical Pharmacology, 85(7), 873鈥?80.PubMed
  71.Karin, M. (2008). The IkappaB kinase鈥攁 bridge between inflammation and cancer. Cell Research, 18(3), 334鈥?42.PubMed
  72.Azevedo, A., Cunha, V., Teixeira, A. L., & Medeiros, R. (2011). IL6/IL6R as a potential key signaling pathway in prostate cancer development. World Journal of Clinical Oncology, 2(12), 384鈥?96.PubMed Central PubMed
  73.Flavell, R. A., Sanjabi, S., Wrzesinski, S. H., & Licona-Limon, P. (2010). The polarization of immune cells in the tumour environment by TGFbeta. Nature Reviews Immunology, 10(8), 554鈥?67.PubMed
  74.Shih, C. M., Lee, Y. L., Chiou, H. L., Hsu, W. F., Chen, W. E., Chou, M. C., et al. (2005). The involvement of genetic polymorphism of IL-10 promoter in non-small cell lung cancer. Lung Cancer, 50(3), 291鈥?97.PubMed
  75.Montuenga, L. M., & Pio, R. (2007). Tumour-associated macrophages in nonsmall cell lung cancer: the role of interleukin-10. European Respiratory Journal, 30(4), 608鈥?10.PubMed
  76.Fini, M. A., Elias, A., Johnson, R. J., Richard, M., & Wright, R. M. (2012). Contribution of uric acid to cancer risk, recurrence, and mortality. Clinical and Translational Medicine, 1, 16.PubMed Central PubMed
  77.Gurda, G. T., Zhang, L., Wang, Y., Chen, L., Geddes, S., Cho, W. C., et al. (2015). Utility of five commonly used immunohistochemical markers TTF-1, Napsin A, CK7, CK5/6 and P63 in primary and metastatic adenocarcinoma and squamous cell carcinoma of the lung: a retrospective study of 246 fine needle aspiration cases. Clinical and Translational Medicine, 4, 16.PubMed Central PubMed
  78.Ganguly, R., Mohyeldin, A., Thiel, J., Kornblum, H. I., Beullen, M., & Nakano, I. (2015). MELK鈥攁 conserved kinase: functions, signaling, cancer, and controversy. Clinical and Translational Medicine, 4, 11.PubMed Central PubMed
  79.Viger, L., Denis, F., Rosalie, M., & Letellier, C. (2014). A cancer model for the angiogenic switch. Journal of Theoretical Biology, 360, 21鈥?3.PubMed
  80.Rius, J., Guma, M., Schachtrup, C., Akassoglou, K., Zinkernagel, A. S., Nizet, V., et al. (2008). NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha. Nature, 453(7196), 807鈥?11.PubMed Central PubMed
  81.Wang, J. Q., & Wu, K. J. (2015). Epigenetic regulation of epithelial-mesenchymal transition by hypoxia in cancer: targets and therapy. Current Pharmaceutical Design, 21(10), 1272鈥?278.PubMed
  82.Gori, B., Ricciardi, S., Fulvi, A., Del Signore, E., & de Marinis, F. (2012). New oral multitargeted antiangiogenics in non-small-cell lung cancer treatment. Future Oncology, 8(5), 559鈥?73.PubMed
  83.Qian, Q., Shi, X., Lei, Z., Zhan, L., Liu, R. Y., Zhao, J., et al. (2014). Methylated +58CpG site decreases DCN mRNA expression and enhances TGF-beta/Smad signaling in NSCLC cells with high metastatic potential. International Journal of Oncology, 44(3), 874鈥?82.PubMed
  84.Polyak, K., & Weinberg, R. A. (2009). Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nature Reviews Cancer, 9(4), 265鈥?73.PubMed
  85.Merikallio, H., Turpeenniemi-Hujanen, T., Paakko, P., Makitaro, R., Riitta, K., Salo, S., et al. (2012). Snail promotes an invasive phenotype in lung carcinoma. Respiratory Research, 13, 104.PubMed Central PubMed
  86.Gonzalez-Arriaga, P., Pascual, T., Garcia-Alvarez, A., Fernandez-Somoano, A., Lopez-Cima, M. F., & Tardon, A. (2012). Genetic polymorphisms in MMP 2, 9 and 3 genes modify lung cancer risk and survival. BMC Cancer, 12, 121.PubMed Central PubMed
  87.Roy, R., Yang, J., & Moses, M. A. (2009). Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. Journal of Clinical Oncology, 27(31), 5287鈥?297.PubMed Central PubMed
  88.Li, W., Li, S., Deng, L., Yang, S., Li, M., Long, S., et al. (2015). Decreased MT1-MMP in gastric cancer suppressed cell migration and invasion via regulating MMPs and EMT. Tumour Biology. doi:10.鈥?007/鈥媠13277-015-3381-7 .
  89.Atkinson, J. J., & Senior, R. M. (2003). Matrix metalloproteinase-9 in lung remodeling. American Journal of Respiratory Cell and Molecular Biology, 28(1), 12鈥?4.PubMed
  90.Gilles, C., Bassuk, J. A., Pulyaeva, H., Sage, E. H., Foidart, J. M., & Thompson, E. W. (1998). SPARC/osteonectin induces matrix metalloproteinase 2 activation in human breast cancer cell lines. Cancer Research, 58(23), 5529鈥?536.PubMed
  91.Yu, H., Kortylewski, M., & Pardoll, D. (2007). Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nature Reviews Immunology, 7(1), 41鈥?1.PubMed
  92.Zeni, E., Mazzetti, L., Miotto, D., Lo Cascio, N., Maestrelli, P., Querzoli, P., et al. (2007). Macrophage expression of interleukin-10 is a prognostic factor in nonsmall cell lung cancer. European Respiratory Journal, 30(4), 627鈥?32.PubMed
  93.Hatanaka, H., Abe, Y., Kamiya, T., Morino, F., Nagata, J., Tokunaga, T., et al. (2000). Clinical implications of interleukin (IL)-10 induced by non-small-cell lung cancer. Annals of Oncology, 11(7), 815鈥?19.PubMed
  94.De Vita, F., Orditura, M., Galizia, G., Romano, C., Roscigno, A., Lieto, E., et al. (2000). Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients. Chest, 117(2), 365鈥?73.PubMed
  95.Pine, S. R., Mechanic, L. E., Enewold, L., Chaturvedi, A. K., Katki, H. A., Zheng, Y. L., et al. (2011). Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer. Journal of the National Cancer Institute, 103(14), 1112鈥?122.PubMed Central PubMed
  96.De Vita, F., Orditura, M., Auriemma, A., Infusino, S., Roscigno, A., & Catalano, G. (1998). Serum levels of interleukin-6 as a prognostic factor in advanced non-small cell lung cancer. Oncology Reports, 5(3), 649鈥?52.PubMed
  97.Chang, K. T., Huang, C. Y., Tsai, C. M., Chiu, C. H., & Lok, Y. Y. (2005). Role of IL-6 in neuroendocrine differentiation and chemosensitivity of non-small cell lung cancer. American Journal of Physiology - Lung Cellular and Molecular Physiology, 289(3), 438鈥?45.
  98.Jumper, C., Cobos, E., & Lox, C. (2004). Determination of the serum matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) in patients with either advanced small-cell lung cancer or non-small-cell lung cancer prior to treatment. Respiratory Medicine, 98(2), 173鈥?77.PubMed
  99.Liu, D., Nakano, J., Ishikawa, S., Yokomise, H., Ueno, M., Kadota, K., et al. (2007). Overexpression of matrix metalloproteinase-7 (MMP-7) correlates with tumor proliferation, and a poor prognosis in non-small cell lung cancer. Lung Cancer, 58(3), 384鈥?91.PubMed
  100.Lin, Y., Bai, L., Chen, W., & Xu, S. (2010). The NF-kappaB activation pathways, emerging molecular targets for cancer prevention and therapy. Expert Opinion on Therapeutic Targets, 14(1), 45鈥?5.PubMed Central PubMed
  101.Moran, C. J., Arenberg, D. A., Huang, C. C., Giordano, T. J., Thomas, D. G., Misek, D. E., et al. (2002). RANTES expression is a predictor of survival in stage I lung adenocarcinoma. Clinical Cancer Research, 8(12), 3803鈥?812.PubMed
  102.Rothwell, P. M., Fowkes, F. G., Belch, J. F., Ogawa, H., Warlow, C. P., & Meade, T. W. (2011). Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet, 377(9759), 31鈥?1.PubMed
  103.Jin, G. H., Hirano, T., & Murakami, M. (2008). Combination treatment with IL-2 and anti-IL-2 mAbs reduces tumor metastasis via NK cell activation. International Immunology, 20(6), 783鈥?89.PubMed
  104.Herbst, R. S. (2004). Review of epidermal growth factor receptor biology. International Journal of Radiation Oncology, Biology, and Physics, 59(2 Suppl), 21鈥?6.
  105.Heinrich, E. L., Walser, T. C., Krysan, K., Liclican, E. L., Grant, J. L., Rodriguez, N. L., et al. (2012). The inflammatory tumor microenvironment, epithelial mesenchymal transition and lung carcinogenesis. Cancer Microenvironment, 5(1), 5鈥?8.PubMed Central PubMed
  106.Sato, M., Shames, D. S., & Hasegawa, Y. (2012). Emerging evidence of epithelial-to-mesenchymal transition in lung carcinogenesis. Respirology, 17(7), 1048鈥?059.PubMed
  
• 作者单位：Lin Shi (1)
  Lingyan Wang (1)
  Jiayan Hou (1)
  Bijun Zhu (1)
  Zhihui Min (1)
  Miaomiao Zhang (1)
  Dongli Song (1)
  Yunfeng Cheng (1)
  Xiangdong Wang (1)
  
  1. Zhongshan Hospital, Shanghai Institute of Clinical Bioinformatics, Fudan University Center for Clinical Bioinformatics, Biomedical Research Center, Fudan University, Shanghai, China
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Oncology
  Cancer Research
  
• 出版者：Springer Netherlands
• ISSN：1573-7233

文摘

Inflammatory cells and mediators are essential components in tumor microenvironment and play decisive roles in the initiation, proliferation, survival, promotion, invasion, or metastasis of lung cancer. Clinical and epidemiologic studies suggested a strong association between inflammation and lung cancer and an influence of immune surveillances and tumor responses to chemotherapeutic drugs, although roles of inflammation in lung cancer remain unclear. The present review outlined roles of inflammation in lung cancer, with particular focus on inflammatory components, types, biomarkers, or principal mechanisms by which the inflammation contributes to the development of lung cancer. The cancer-associated inflammatory cells (CICs) should be furthermore defined and include cancer-specific and interacted cells with inflammatory or inflammation-like characteristics, e.g., innate or adaptive immune cells and cancer tissue cells. We also discuss targeting potentials of inflammation in the prevention and treatment of lung cancer. The diversity of cancer-related inflammatory microenvironment is instrumental to design novel therapeutic approaches for lung cancer.